SG11202100112YA - Methods of using a gip/glp1 co-agonist for therapy - Google Patents
Methods of using a gip/glp1 co-agonist for therapyInfo
- Publication number
- SG11202100112YA SG11202100112YA SG11202100112YA SG11202100112YA SG11202100112YA SG 11202100112Y A SG11202100112Y A SG 11202100112YA SG 11202100112Y A SG11202100112Y A SG 11202100112YA SG 11202100112Y A SG11202100112Y A SG 11202100112YA SG 11202100112Y A SG11202100112Y A SG 11202100112YA
- Authority
- SG
- Singapore
- Prior art keywords
- glp1
- gip
- agonist
- therapy
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702061P | 2018-07-23 | 2018-07-23 | |
| US201862730565P | 2018-09-13 | 2018-09-13 | |
| US201862740619P | 2018-10-03 | 2018-10-03 | |
| PCT/US2019/042817 WO2020023382A1 (en) | 2018-07-23 | 2019-07-22 | Methods of using a gip/glp1 co-agonist for therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100112YA true SG11202100112YA (en) | 2021-02-25 |
Family
ID=68387389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100112YA SG11202100112YA (en) | 2018-07-23 | 2019-07-22 | Methods of using a gip/glp1 co-agonist for therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200023040A1 (en) |
| EP (1) | EP3826716A1 (en) |
| JP (2) | JP2021533094A (en) |
| KR (1) | KR20210024583A (en) |
| CN (1) | CN112512633A (en) |
| AU (2) | AU2019309796B2 (en) |
| BR (1) | BR112020026372A2 (en) |
| CA (1) | CA3107344A1 (en) |
| IL (1) | IL280258A (en) |
| MA (1) | MA53390A (en) |
| MX (1) | MX2021000794A (en) |
| SG (1) | SG11202100112YA (en) |
| TW (1) | TW202019460A (en) |
| WO (1) | WO2020023382A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642935A (en) * | 2019-09-25 | 2020-01-03 | 成都奥达生物科技有限公司 | Tirapapotide analogue |
| TW202228762A (en) * | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | Therapeutic uses of tirzepatide |
| MX2023000303A (en) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Co-agonists at glp-1 and gip receptors suitable for oral delivery. |
| CN116710462A (en) * | 2021-01-20 | 2023-09-05 | 维京治疗公司 | Compositions and methods for treating metabolic disorders and liver diseases |
| JP2024508745A (en) * | 2021-02-17 | 2024-02-28 | イーライ リリー アンド カンパニー | GIP/GLP1 dual agonist treatment method |
| CN117750953A (en) * | 2021-06-25 | 2024-03-22 | 伊莱利利公司 | Methods for treating obstructive sleep apnea |
| WO2023141044A1 (en) * | 2022-01-18 | 2023-07-27 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
| TW202330584A (en) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Prodrugs and uses thereof |
| WO2024006662A1 (en) * | 2022-06-30 | 2024-01-04 | Eli Lilly And Company | Tirzepatide compositions and use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117742C2 (en) | 2010-03-01 | 2018-09-25 | Елі Ліллі Енд Компані | DEVICE FOR AUTOMATIC IMMEDIATE INJECTION WITH DELAY MECHANISM, INCLUDING DUAL DESTINATION |
| JOP20200119A1 (en) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | Gip and glp-1 co-agonist compounds |
| TWI705820B (en) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1 agonist compositions |
-
2019
- 2019-07-22 EP EP19795373.0A patent/EP3826716A1/en active Pending
- 2019-07-22 WO PCT/US2019/042817 patent/WO2020023382A1/en unknown
- 2019-07-22 MX MX2021000794A patent/MX2021000794A/en unknown
- 2019-07-22 CN CN201980049182.2A patent/CN112512633A/en active Pending
- 2019-07-22 SG SG11202100112YA patent/SG11202100112YA/en unknown
- 2019-07-22 JP JP2021503849A patent/JP2021533094A/en active Pending
- 2019-07-22 TW TW108125856A patent/TW202019460A/en unknown
- 2019-07-22 US US16/518,513 patent/US20200023040A1/en not_active Abandoned
- 2019-07-22 CA CA3107344A patent/CA3107344A1/en active Pending
- 2019-07-22 KR KR1020217002208A patent/KR20210024583A/en not_active Application Discontinuation
- 2019-07-22 AU AU2019309796A patent/AU2019309796B2/en active Active
- 2019-07-22 MA MA053390A patent/MA53390A/en unknown
- 2019-07-22 BR BR112020026372-9A patent/BR112020026372A2/en unknown
-
2021
- 2021-01-18 IL IL280258A patent/IL280258A/en unknown
- 2021-07-02 US US17/366,453 patent/US20210338781A1/en active Pending
-
2022
- 2022-07-04 JP JP2022107916A patent/JP2022130686A/en active Pending
- 2022-12-22 AU AU2022291585A patent/AU2022291585A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112512633A (en) | 2021-03-16 |
| CA3107344A1 (en) | 2020-01-30 |
| TW202019460A (en) | 2020-06-01 |
| IL280258A (en) | 2021-03-01 |
| KR20210024583A (en) | 2021-03-05 |
| JP2021533094A (en) | 2021-12-02 |
| US20200023040A1 (en) | 2020-01-23 |
| US20210338781A1 (en) | 2021-11-04 |
| MA53390A (en) | 2021-06-02 |
| BR112020026372A2 (en) | 2021-03-23 |
| AU2019309796A1 (en) | 2021-01-21 |
| MX2021000794A (en) | 2021-04-12 |
| AU2022291585A1 (en) | 2023-02-02 |
| WO2020023382A1 (en) | 2020-01-30 |
| EP3826716A1 (en) | 2021-06-02 |
| AU2019309796B2 (en) | 2022-10-13 |
| JP2022130686A (en) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280258A (en) | Methods of using a gip/glp1 co-agonist for therapy | |
| IL279827A (en) | Gip/glp1 co-agonist compounds | |
| IL280159A (en) | Method of using a gip/glp1 co-agonist for diabetes | |
| GB201801517D0 (en) | A method of determining a state energy | |
| IL277194A (en) | Means and methods for glycoprofiling of a protein | |
| GB201915444D0 (en) | Method of using a blockchain | |
| GB201804627D0 (en) | A method of communicating | |
| GB201805954D0 (en) | A method | |
| EP3776213A4 (en) | Method of debugging a processor | |
| GB201902908D0 (en) | Method of using a blockchain | |
| GB201810544D0 (en) | Method of debugging a device | |
| IL281552A (en) | Methods and means for preparing a library for sequencing | |
| ZA202102795B (en) | Method of treatment of a surface | |
| SG11202105280QA (en) | Method of identifying a structure | |
| SG11202105311VA (en) | Method of identifying a structure | |
| GB201813722D0 (en) | A method | |
| EP3710772C0 (en) | A method for cleaning of a device | |
| ZA202006375B (en) | A method of carbonizate purification | |
| NO20170008A1 (en) | A process for treatment of fly ash | |
| ZA202102697B (en) | Method of treatment of a surface | |
| GB201910918D0 (en) | Method of contrilling a robotic havesting device | |
| GB201813730D0 (en) | A method | |
| GB201809530D0 (en) | A method | |
| GB201808039D0 (en) | A method | |
| GB201907499D0 (en) | Method of using a blockchain |